Tuesday, March 21, 2006

BiDil Sales Are Disappointing

From The New York Times:
A new drug hailed last year as a breakthrough for black heart patients has become a major disappointment for its maker, NitroMed, and the company announced yesterday that two top executives involved in bringing the product to market had resigned...

The American Heart Association officially designated BiDil as a major treatment advance after research indicated it could extend the lives of black heart-failure patients by 43 percent over 18 months. And some financial analysts had predicted annual sales could eventually reach $825 million, based on BiDil's use by about 750,000 black heart failure patients...

The company also was criticized for pricing the drug at $1.80 a pill, about twice what some financial analysts had predicted. Some patients take up to six pills a day.
Technorati Tags: , , , , ,

No comments: